Pharma Articles
Articles on key issues related to the pharma industry from the heads of leading pharmaceutical companies and pharma industry experts across the globe. The pharma industry articles' section focuses on current and emerging issues in areas such as Strategic developments in the pharma industry, pharmaceutical R&D, drug discovery, clinical trials, pharmaceutical manufacturing, biopharmaceuticals, and information technology.
The Exosome Manufacturing Gap
Why the Biggest Crisis in EV Therapeutics Isn't Science
Extracellular vesicles EVs including exosomes have been touted as the next big thing in the biopharmaceuticals arena for the last decade Exosomes are naturally occurring vesicles of nanosized nm which are secreted by almost all eukaryotic cells The exosomes have been differentiated from other vesic...
Why Pharma's Safety Net Must Follow the Medicine Home
Serialisation chainofcustody verification and a growing web of regulatory requirements are intended to protect patients Layers of checks have been designed to ensure that what leaves the manufacturer
Architecting the Modern MICC for Life Sciences GCCs
Untangling the Tapestry of Care
Imagine a bewilderingly busy therapeutic hub where thousands of messages arrive simultaneously from every corner of the globe Thousands of people hundreds of languages A Medical Information Contact Centre MICC is precisely this the central nervous system for pharmaceutical operations
Nanovaccines
Emerging Significant Players in the Era of Vaccination
Vaccination represents the most efficacious tool for the prevention as well as control of infectious diseases accentuating the importance of safe and effective vaccines for preserving global health and enhancing economic growth Moreover the COVID pandemic of further highlighted the imperative role...
Emerging Technologies in Pharmaceutical Sciences
From discovery to delivery, the transformation has already begun
The pharmaceutical industry has always been defined by two constants the extraordinary complexity of what it does and the extraordinary cost of doing it Bringing a single drug from discovery to approval has historically taken to years and cost an average of US billion
Moving from Code to Consequence
Confronting AI hallucinations in predictive toxicology
The global pharmaceutical sector is undergoing a profound paradigm shift transitioning rapidly from reactive preclinical safety testing to proactive in silico trial simulation Driven by the critical economic necessity to mitigate latestage clinical attrition generative artificial intelligence platfo...
Navigating Regulatory Frameworks: “Generic Approvals in Latin America’s Two Giants- Brazil & Mexico
The pharmaceutical products that can often be substituted with a previously approved brandnew product manufactured without the innovators license and marketed upon the expiry of the patent are called as generics Generics account for the of the global pharmaceutical prescription sales The Generic Dr...
Beyond The Needle
Navigating Mucosal Toxicity in Next-gen Oral Peptides
The therapeutic peptide market worldwide is growing more than ever with a change of trends from a parenteral injection approach to more patientcompliant oral solid dosage forms Unfortunately crossing the intestinal lumen via a parenteraltooral administration route with such a big macromolecule pepti...
M&A, Partnerships & Ecosystem Models in Biopharma
Why the Future of Biologics Will Depend as Much on Partnerships as on Molecules
Biopharma dealmaking is entering a more disciplined phase The industry is still looking outward to growth but the model has changed Large acquisitions remain important yet companies are increasingly using a broader set of tools licensing codevelopment manufacturing partnerships regional supply agree...
Blockchain for Data Integrity in Biopharma
Myth or Reality?
Data integrity in the Biopharmaceutical industry is a key requirement for maintaining public trust in patient safety and product quality while supporting regulatory compliance It provides assurance that data generated during the entire lifecycle of a pharmaceutical product are complete accurate reli...
Beyond the Cold Chain
Lyophilisation and spray drying as superior biologic platforms
The global healthcare landscape is witnessing a seismic shift Biological drugs once considered a niche frontier have now become the vanguard of modern medicine successfully addressing some of the most complex health challenges of our time including refractory cancers rare genetic disorders and chron...
Applying Human Factors Engineering to Generic Combination Products
Human factors engineering HFE is a key element in developing an effective medical device and focuses on ensuring that a devices design is wellmatched to its intended users In contrast to developing an entirely new combination product where the HFE process involves a variety of activities
The Role of Bioinformatics in Accelerating Translational Research
The advent of highthroughput technologies has resulted in a massive influx of biological data into public repositories For example platforms such as the Sequence Read Archive SRA have amassed over petabytes of sequencing data housing millions of datasets generated from global studies Kodama et al...
From Gene Editing to Network Medicine
How CRISPR, Programmable Gene Circuits, and AI-Driven Intrinsic Network Pharmacology May Transform Next-Generation Drug Discovery
Biomedicine is undergoing a profound transformation driven by the convergence of genomics artificial intelligence and systems biology Traditional drug discovery largely focused on identifying a single molecular target and designing a compound capable of modulating that target While this strategy has...
Integrated by Design
Strategic pathways for drug-led combination products
Combination products which integrate a drug andor biologic component with a medical device component are increasing globally Because they do not fit neatly into a single category regulation of these products can be difficult to navigate
